Bifogade filer
Kurs
+2,04%
Likviditet
0,11 MSEK
Kalender
Est. tid* | ||
2025-08-29 | 10:00 | Bokslutskommuniké 2025 |
2025-05-15 | N/A | Extra Bolagsstämma 2025 |
2025-05-09 | 08:00 | Kvartalsrapport 2025-Q3 |
2025-02-07 | - | Kvartalsrapport 2025-Q2 |
2024-11-04 | - | X-dag ordinarie utdelning VSD B 0.00 SEK |
2024-11-01 | - | Årsstämma |
2024-10-28 | - | Kvartalsrapport 2025-Q1 |
2024-08-30 | - | Bokslutskommuniké 2024 |
2024-04-19 | - | Kvartalsrapport 2024-Q3 |
2024-04-12 | - | Extra Bolagsstämma 2024 |
2024-02-09 | - | Kvartalsrapport 2024-Q2 |
2023-10-27 | - | Kvartalsrapport 2024-Q1 |
2023-09-25 | - | X-dag ordinarie utdelning VSD B 0.00 SEK |
2023-09-22 | - | Årsstämma |
2023-08-31 | - | Bokslutskommuniké 2023 |
2023-05-04 | - | Kvartalsrapport 2023-Q3 |
2023-02-09 | - | Kvartalsrapport 2023-Q2 |
2022-10-27 | - | Kvartalsrapport 2023-Q1 |
2022-10-07 | - | X-dag ordinarie utdelning VSD B 0.00 SEK |
2022-10-06 | - | Årsstämma |
2022-08-30 | - | Bokslutskommuniké 2022 |
2022-07-05 | - | Extra Bolagsstämma 2022 |
2022-05-04 | - | Kvartalsrapport 2022-Q3 |
2022-02-11 | - | Kvartalsrapport 2022-Q2 |
2021-10-22 | - | Kvartalsrapport 2022-Q1 |
2021-10-06 | - | X-dag ordinarie utdelning VSD B 0.00 SEK |
2021-10-05 | - | Årsstämma |
2021-08-30 | - | Bokslutskommuniké 2021 |
2021-05-12 | - | Kvartalsrapport 2021-Q3 |
2021-02-12 | - | Kvartalsrapport 2021-Q2 |
2020-11-12 | - | Kvartalsrapport 2021-Q1 |
2020-10-08 | - | X-dag ordinarie utdelning VSD B 0.00 SEK |
2020-10-07 | - | Årsstämma |
2020-08-31 | - | Bokslutskommuniké 2020 |
2020-05-15 | - | Kvartalsrapport 2020-Q3 |
2020-05-04 | - | Extra Bolagsstämma 2020 |
2020-02-14 | - | Kvartalsrapport 2020-Q2 |
2019-11-01 | - | Kvartalsrapport 2020-Q1 |
2019-10-10 | - | X-dag ordinarie utdelning VSD B 0.00 SEK |
2019-10-09 | - | Årsstämma |
2019-08-30 | - | Bokslutskommuniké 2019 |
2019-05-16 | - | Kvartalsrapport 2019-Q3 |
2019-02-14 | - | Kvartalsrapport 2019-Q2 |
2018-10-30 | - | Kvartalsrapport 2019-Q1 |
2018-10-17 | - | X-dag ordinarie utdelning VSD B 0.00 SEK |
2018-10-16 | - | Årsstämma |
2018-08-31 | - | Bokslutskommuniké 2018 |
2018-05-16 | - | Kvartalsrapport 2018-Q3 |
2018-02-14 | - | Kvartalsrapport 2018-Q2 |
2017-10-30 | - | Kvartalsrapport 2018-Q1 |
2017-10-02 | - | X-dag ordinarie utdelning VSD B 0.00 SEK |
2017-09-29 | - | Årsstämma |
2017-08-30 | - | Bokslutskommuniké 2017 |
2017-05-22 | - | Kvartalsrapport 2017-Q3 |
2017-02-20 | - | Kvartalsrapport 2017-Q2 |
2017-01-25 | - | Extra Bolagsstämma 2017 |
2016-11-07 | - | Kvartalsrapport 2017-Q1 |
2016-08-29 | - | X-dag ordinarie utdelning VSD B 0.00 SEK |
2016-08-26 | - | Bokslutskommuniké 2016 |
2016-05-26 | - | Kvartalsrapport 2016-Q3 |
2016-02-25 | - | Kvartalsrapport 2016-Q2 |
2015-11-26 | - | Kvartalsrapport 2016-Q1 |
2015-08-27 | - | Bokslutskommuniké 2015 |
Beskrivning
Land | Sverige |
---|---|
Lista | Spotlight |
Sektor | Hälsovård |
Industri | Medicinteknik |
VibroSense Dynamics has delivered an instrument to the Chemnitz University of Technology, which is a new customer in Germany. The deal is designed as a rental agreement, which is estimated to provide a total income of at least EUR 18,000 over three years. The delivery of VibroSense Meter® II and Diabetic Foot Screening is the second in a short time to Germany and the company's launch in this new market.
Dr. Falk Zaumseil is a Professor of Movement Science and researcher in Biomechanics at Chemnitz University of Technology. He, together with two colleagues, will use the VibroSense Meter® II in a research study.
The university is strongly committed to the next generation of researchers. Nurturing young researchers is a focus of the work at Chemnitz University of Technology. It is a cosmopolitan university that combines technology and natural sciences as well as mathematics with the humanities, social sciences and economics.
"The order and delivery to Chemnitz is further proof that we are taking important steps forward on the German market. Chemnitz University of Technology is not the "typical diabetes customer" but their order and the need for our instrument in research confirms the breadth of opportunities we have in Germany. We have continued focus and expect a positive development on the German market", says Hans Wallin, CEO of VibroSense Dynamics AB.
Contact
Hans Wallin, CEO VibroSense Dynamics AB
Tel: +46 40 88 026
Email: info@vibrosense.com
www.vibrosense.com
"The new Gold Standard for reliable
detection of nerve damage"
About VibroSense Dynamics AB (publ)
VibroSense Dynamics AB (publ) develops and sells medical technology products and services for diagnostic support for nerve damage in the hands and feet. The method involves measuring and quantifying the ability to feel vibrations at several frequencies. The company's customers are diabetes clinics, occupational health care, hospitals, health centers and researchers.
Our vision is that the company's products should be a standard instrument in all neurological examinations to detect early signs of changes in sensation so that patients and their caregivers can implement preventive measures that prevent, reduce or delay the onset of nerve damage in the hands and feet.